CAS |
7689/3/4 |
Chinese Name |
喜树碱 |
English Name |
Camptothecine |
Synonyms |
(S)-(+)-Camptothecin;CPT;NSC-100880 |
Molecular Formula |
C20H16N2O4 |
Molecular Weight |
348.35 |
Solubility |
Soluble in DMSO ≥5mg/mL |
Purity |
HPLC≥98% |
Appearance |
Light yellow to yellow Solid |
Storage |
Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
EC |
EINECS 444-280-6 |
MDL |
MFCD00081076 |
SMILES |
O=C1C2=C([C@@](O)(CC)C(OC2)=O)C=C(N1C3)C(C3=C4)=NC5=C4C=CC=C5 |
InChIKey |
VSJKWCGYPAHWDS-FQEVSTJZSA-N |
InChI |
InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1 |
PubChem CID |
24360 |
Target Point |
Topoisomerase |
Passage |
DNA Damage/DNA Repair |
Background |
It is a DNA topoisomerase I (Topo I) inhibitor with strong anti-tumor activity. |
Biological Activity |
Campathecin 是有效的 DNA拓扑异构酶 I 抑制剂, IC50 值为 679 nM[1-3]。 |
IC50 |
Topoisomerase I:679nM (IC50) [1-3] |
In Vitro |
[3H]拓扑异构酶I的BrCPT标记由于DNA的存在而大大增强; 很少标记分离的拓扑异构酶I或分离的DNA发生者。即使在DNA存在下,拓扑异构酶I的[3H] BrCPT标记也被喜树碱抑制,这表明CPT和BrCPT都与DNA拓扑异构酶I二元复合物上的相同位点结合[1]。随着喜树碱浓度的增加,闭合的环状pRR322 DNA(形式I)被转化为带切口的环状DNA(形式11)。喜树碱的这种明显的切口活性需要DNA拓扑异构酶I [2]。 |
Kinase Experiment |
每种反应混合物(200μL,总体积)含有2μg超螺旋pDPT2789 DNA(2.4nM质粒浓度),50mM Tris-HCl,pH 7.5,120mM KCl,10mM MgCl 2,0.5mM EDTA,0.05%二甲基亚砜,1%甲醇,100μg/ mL BSA,4.3ng小牛胸腺拓扑异构酶I(0.26nM)和CPT衍生物。将反应混合物在37℃温育,并在指定的时间取出20-μL等分试样并通过加入5μLSDS/ Ficoll终止混合物终止(终浓度,0.5%SDS,2%Ficoll,0.025%溴酚)蓝色)。将样品上样到1%琼脂糖凝胶上并通过电泳分析。 |
Data Literature Source |
[1]. Hertzberg RP, et al. Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site. J Biol Chem. 1990 Nov 5; 265 (31) :19287-95. [2]. Hsiang YH, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985 Nov 25; 260 (27) :14873-8. [3]. Luzzio MJ, et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. |
Unit |
Bottle |
Specification |
20mg 10mM*1mL in DMSO 100mg |